Navigation path


This page was published on 05/03/2007
Published: 05/03/2007

   Special Collections

Published: 5 March 2007  
Related category(ies):
Health & life sciences  |  Special Collections  |  Research policy


Add to PDF "basket"

EU supports cell therapy project, fosters dialogue with patient groups

The EU has given the green light to a new project that focuses on the most common and debilitating form of muscular dystrophy, known as Duchenne Muscular Dystrophy (DMD). The project, called MYOAMP, has identified a gap in the current body of knowledge concerning stem cell therapies for DMD, and aims to pool existing studies into a single knowledge base that can be used as a synthesised resource in a final preparatory stage leading to clinical studies. MYOAMP is unique in that the project consortium is not only comprised of research institutions and SMEs, but includes patient organisations adding invaluable insight to the project.

MYOAMP will apply a novel approach to existing studies. © MYOAMP
MYOAMP will apply a novel approach to existing studies by influencing protein production via mRNA.
DMD affects over 30 000 people in Europe, a number equal to the population of Monaco, where the MYOAMP consortium gathered recently to officially launch the three year project funded under FP6.

MYOAMP is basing their research on a newly designed technique known as ‘exon-skipping'. An exon is a portion of a gene that codes for a particular protein, and when the gene is responsible for proteins harmful to the organism, as is the case in DMD, experts have developed a technique to ‘skip' the exon, leaving them with a new protein offering potential therapeutic qualities.

The project brings together experts from across Europe to define best practice procedures for transferring human muscle stem cells in Good Manufacturing Practice (GMP) conditions to be used in exon-skipping to treat DMD.

Currently, little is known about growing human cells in GMP conditions, which certifies that they are suitable for clinical trials. Several studies have been carried out on animals, but never in a systematic manner, making comparisons difficult. MYOAMP aims to change that through the dedicated study of the amplification of quality myogenic (muscle) stem cells used in cell therapy techniques.

The expected result of the project is the definition of protocols in obtaining amplified human stem cells allowing for optimised efficiency in clinical trials. Additionally, MYOAMP will provide guidelines and standard operative procedures for growing these cells that will address technical, ethical and safety issues under GMP conditions.

To maximise the impact of the project, MYOAMP has chosen from the beginning to include patient associations throughout the development of the project. International patient associations such as the Duchenne Parent Project in France and the UK, the Association Monégasque Contre les Myopathies, and the Association Française contre les Myopathies are all participating. As such, the end-users of the research will be the first to learn of the progress of the project. Participants feel this is the best way to ensure public health officials understand the necessity of supporting clinical trials.

Convert article(s) to PDF

No article selected


Search articles

To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

MYOAMP meeting report
MYOAMP coordinator homepage
Health in FP7

  Top   Research Information Center